Eligard 2017 U.S. PROMOTIONAL AUDIT REPORT

Published July 2018 • 19 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Eligard through reportable promotional activity in 2017 and how does this compare to its peer set in the Prostate Cancer market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Tolmar’s depth of coverage vary within key specialties (e.g., Urology and Hematology/Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Eligard throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Eligard in 2017?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available – covering payments to more than 975,000 U.S. healthcare professionals.
• Over 3,900 paid interactions across 2,000 physicians made on behalf of Eligard were carefully examined to support our analysis. In addition, interaction data from 8 peer products (e.g. Firmagon, Jevtana, Lupron Depot, Provenge, Xofigo, Xtandi, Zoladex, and Zytiga ) was leveraged to provide benchmarking and market insights.